Natera Holder Sues Leaders Over Misrepresented Tests, Sales (1)

Natera Inc.’s directors and top executives allegedly misrepresented the accuracy of the company’s genetic tests and its sales and billing practices before the stock’s record selloff, according to a shareholder derivative suit.

The suit filed Tuesday follows a class action by another Natera shareholder who brought similar allegations that the company violated the Securities Exchange Act in April 2022, also in US District Court for the Western District of Texas.

The newest suit highlights how the alleged misrepresentations negatively impacted Natera’s stock price, which dropped as much as 52% on March 9, 2022 after a report by Hindenburg Research ...